Objective: Identification of patients with high-risk asymptomatic carotid plaques remains an elusive but essential step in stroke prevention. Inflammation is a key process in plaque destabilization and a prelude to clinical sequelae. There are currently no clinical imaging tools to assess the inflammatory activity within plaques. This study characterized inflammation in atherosclerosis using dual-targeted microparticles of iron oxide (DT-MPIO) as a magnetic resonance imaging (MRI) probe.
an annual stroke risk of 1% to 2% 1 for asymptomatic threshold disease, justifying surgery or stenting is more difficult. Nonetheless, asymptomatic benign atherosclerotic lesions can go on to become unstable and lead to thromboembolic stroke, but currently, there is no reliable imaging tool to discriminate between stable and vulnerable asymptomatic lesions. Promising noninvasive imaging techniques are being developed to interrogate plaque vulnerability in vivo. 2 Molecular magnetic resonance (MR) imaging (MRI) has the distinct advantage of providing precise soft tissue and functional information in vivo by acquiring different contrast weightings, enabling coregistration of molecular anatomic information into a single imaging modality. 3, 4 Superparamagnetic iron oxide (SPIO) particles have become favored MR contrast agents because of a known biocompatibility profile, significant contrast effect, and ease of production. 4 Iron oxide particles increase sensitivity and facilitate diagnosis by shortening transverse T2 and T2* relaxation times, resulting in hypointense signals that appear darker on T2-and T2*-weighted MRI ("negative" contrast). 4 Molecular MRI comprises "passive" and "active" imaging strategies. Ultrasmall SPIO (USPIO) have been used as passive contrast agents to identify plaque macrophages as surrogate markers of plaque inflammation in assessing atherosclerosis in human and animal models. 5, 6 "Active" molecular imaging involves direct reporting of specific molecular events, which mandates the use of a specific targeting system. Target specificity of contrast agents can be achieved through conjugation of a variety of targeting ligands, such as monoclonal antibodies, antibody fragments, peptides, to functional groups on the surface of iron oxide particles. 7 Inflammation is a key driver of plaque instability. Macrophages play a vital role in plaque destabilization, converting chronic stable lesions into acute unstable ones with the potential for thromboembolism. Monocyte recruitment into vascular tissues is promoted by the overexpression of adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM-1 [cluster of differentiation(CD)106]), and P-selectin (CD62P), on the activated endothelium. 8, 9 VCAM-1 is also expressed on activated smooth muscle cells (SMCs) and macrophages, both of which are major plaque constituents. 10 Exploiting the abundance and critical functions of these inducible adhesion molecules, we developed antibodyconjugated SPIO particles directed at VCAM-1 and Pselectin on human carotid plaque tissues as MRI probes for visualizing inflammation. 11 These molecular MRI probes have been used to identify and differentiate the potentially high-risk inflamed plaques from the noninflamed ones within the asymptomatic plaque population by ex vivo MRI. 11 Recently, microparticles of iron oxide (MPIO) was used in imaging endovascular targets. 12 Compared with USPIO and SPIO, the larger MPIO has a greater iron oxide content and can thus generate significant MR contrast effect to enable detection of vascular targets in vivo.
In this study, we have developed fluorescent-labelled dual-ligand MPIO against VCAM-1 and P-selectin to act as a contrast agent to render adhesion molecules visible on MR. Adhesion molecules were detected and characterized in an in vitro and in vivo apolipoprotein E deficient (ApoE e/e ) mouse model. The extent to which dual-targeted MPIO (DT-MPIO) induced MR signal tracks of adhesion molecules and inflammation by in vivo MRI was evaluated. Further, we sought to determine whether asymptomatic carotid plaques could be distinguished by the degree of inflammation exhibited using these MRI probes in an in vivo model.
METHODS
Synthesis of fluorescent-labeled dual-ligand MPIO. MPIO (1-mm diameter; Dynabeads MyOne; Invitrogen, Carlsbad, Calif) with p-toluenesulfonyl (tosyl) reactive surface groups were used for conjugation of purified monoclonal rat antimouse antibody for VCAM-1 (BD Biosciences, San Jose, Calif), purified monoclonal mouse antimouse antibody for P-selectin (Santa Cruz Biotechnology, Dallas, Tex), and fluorescein cadaverine (Molecular Probes/Thermo Fisher, Waltham, Mass). Control immunoglobulin G (IgG)-MPIO and single-targeted MPIO were conjugated with antibody for IgG-1 (monoclonal rat antimouse antibodies for IgG-1; AbD Serotec, Kidlington, United Kingdom), VCAM-1, or P-selectin.
Animals and in vivo administration of dual-MPIO. All animal experiments were performed in accordance with the United Kingdom Scientific Procedures Act (1986) and local ethical approval. Homozygous ApoE e/e mice (70 weeks old) were fed a standard mouse chow diet until the day of the experiment. DT-MPIO or control IgG-MPIO were injected with 5 mg iron/kg body Immunohistochemistry of the aortic root. At the end of MPIO circulation or imaging, the mouse was euthanized, and serial cryostat sections (6 mm thickness) of aortic root were prepared. Three levels of sections were chosen: at the level of aortic valves with three semilunar leaflets and at 150 mm above and below this level. To determine the distribution and localization of MPIO in the aortic root, serial sections at these levels underwent immunostaining for VCAM-1, P-selectin, endothelial cells (CD31; Abcam, Cambridge, Mass), macrophages (monocyte/macrophage marker antibody 2; Abcam), and SMCs (a-smooth muscle actin [a-SMA]; Abcam). Lipid staining by Oil Red O was used to visualize the lesion area. Whole-slide images were produced using an Olympus IX-83 inverted microscope (Olympus, Melville, NY). Histologic staining in all images was quantified in a standardized and objective way using ImageJ software (National Institutes of Health, Bethesda, Md). The stained area of VCAM-1, P-selectin, CD31, monocyte/macrophage marker antibody, a-SMA, and MPIO were quantified as a percentage of the total aortic root area. The mean of stained area percentage at all three levels of histologic images per mouse was calculated.
ARTICLE HIGHLIGHTS
Implantation of shear stress-modifying cuff in carotid arteries. The shear stress-modifying cuff (provided by authors C.M. and K.K.B.) and implantation procedure were described in previous studies. 13 The cone-shaped inner lumen is imperative for creating defined regions of low shear stress (LSS) upstream, high shear stress (HSS) within the cuff, and oscillatory shear stress (OSS) downstream within the common carotid artery (CCA). 13 At age 18 weeks, the ApoE e/e mice were fed an atherogenic diet 2 weeks before cuff implantation until the day of scanning. At week 20, surgical implantation of the shear stress-modifying cuff was performed on one of the CCAs, and the other CCA was left untreated as a control.
In vivo MRI of carotid arteries. At age 29 weeks (ie, 9 weeks after collar placement) ApoE e/e mice underwent in vivo MRI of carotid arteries. Histology of carotid arteries. At the end of the scanning session, the ApoE e/e mice were euthanized, the arterial tree was perfusion fixed, and the cuff was removed. To determine which phenotypes of carotid plaques were targeted by DT-MPIO, serial 4-mm-thick paraffin sections of the entire carotid artery across all three shear-stress regions underwent staining for iron (Perls') and connective tissue (picrosirius red), and immunostaining for macrophages (Mac-3), and SMCs (a-SMA). Microscopy was performed.
Detailed methodology is available in the Supplementary Methods (online only).
RESULTS
Specificity and efficacy of dual-MPIO. The study used three key cell types that constituent a plaque: the mouse C166 endothelial cell (EC), smooth muscle cell (MOVAS), and macrophage (RAW 264.7) cell lines (American Type Culture Collection, Manassas, Va). These cell-types were stimulated by tumor necrosis factor (TNF)-a to induce expression of VCAM-1 or P-selectin, or both (Fig 1, A) . Activated ECs expressed both markers (Fig 1, A, top) , whereas activated SMCs and activated macrophages expressed only VCAM-1 (Fig 1, A, middle and bottom) . Activated ECs, SMCs, and macrophages expressing VCAM-1 or P-selectin, or both, were targeted by fluorescent-labeled DT-MPIO (Fig 1, A, right panel) . MPIO conjugated with nonspecific IgG was used as the control. Compared with single-ligand targeted MPIO, dualconjugated MPIOs demonstrated more efficient targeting for activated ECs as a result of the synergistic relationship between VCAM-1 and P-selectin (Fig 1, B) .
To further examine the specificity of DT-MPIO, the stimulated cells were preblocked with either of the single VCAM-1 antibody or P-selectin antibody, or both antibodies together. DT-MPIO binding was significantly reduced in cells preblocked with either of the single antibodies and was almost absent when both target sites were blocked by both antibodies (Fig 1, C) . These data corroborated with the high specificity of DT-MPIO to the target sites of VCAM-1 and P-selectin.
To investigate the efficacy of DT-MPIO binding, the three cell lines were stimulated with different doses of TNF-a to induce varying degrees of inflammation. We observed that the higher the dose of TNF-a used, the greater the degree of inflammation, as indicated by the higher level of DT-MPIO showed a synergistic relationship between VCAM-1 and P-selectin with a significantly enhanced binding efficiency, compared to either V-MPIO or P-MPIO alone (n ¼ 9). Scale bar ¼ 50 mm. C, Stimulated EC were initially treated with antibody (Ab) against VCAM-1 (V-Ab), P-selectin (P-Ab), or both (PV-Ab) to block the target sites on the cells before incubation with DT-MPIO. In the control, stimulated cells were not pretreated by any antibodies before incubation with DT-MPIO. These cells were bound by abundant amount of DT-MPIO as shown in green fluorescence signal. The stimulated cells pretreated by P-Ab had P-selectin target sites blocked, leaving only VCAM-1 to be targeted by the DT-MPIO. Hence, DT-MPIO binding was significantly reduced, demonstrated by the low green fluorescence signal. Likewise, DT-MPIO binding was significantly reduced in cells pretreated by V-Ab. When both target sites were blocked by PV-Ab, minimal DT-MPIO binding was observed (n ¼ 9). The bars show mean 6 standard error of the mean. Three independent experiments were performed, and three images were used as quantification in each independent experiment. *P < .05. Scale bar ¼ 50 mm.
VCAM-1 or P-selectin expression, or both; hence, a greater amount of DT-MPIO binding to the cells (Fig 2, A, left panel). DT-MPIO binding not only increased with greater degree of inflammation but also significantly correlated with the cell expression of VCAM-1 and P-selectin (Fig 2, A, right panels). To further examine the binding efficiency, the stimulated cells were incubated with DT-MPIO for up to 4 hours. The cell-bound DT-MPIO was detected as early as 15 minutes after stimulation, with optimal uptake between 1 and 2 hours (Fig 2, B ).
Cytotoxicity and biodistribution of dual-MPIO. An MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was performed to evaluate the cytotoxicity of DT-MPIO in the three cell lines. Cell viability remained high in all cell lines after 24 hours of incubation with DT-MPIO at doses ranging from 0 to 2 mg/mL. We observed no significant cytotoxicity at the concentration used for the subsequent in vivo study (1 mg/mL, equivalent to 5 mg iron/kg) (Fig 3, A) . We next examined the in vivo biodistribution of DT-MPIO from 30 minutes to 72 hours after intravenous administration (Fig 3, B) . MPIO was quantified as the mass of magnetic particles per mg of tissue. MPIO uptake occurred in all tissues as early as 30 minutes after injection, with minimal retention by lung tissue. The rapid uptake of MPIO by the spleen and liver continued up to 48 hours, as expected. No ill effects or symptoms were observed up to 72 hours after MPIO administration.
Determination of optimal imaging time window by histology, ex vivo in situ MRI, and in vivo MRI. Firstly, we performed in vivo administration of DT-MPIO, which was allowed to circulate in ApoE e/e mice up to 2 hours before histology. Immunostaining on serial aortic root sections revealed DT-MPIO targeting the inflamed plaque as early . The cell binding of DT-MPIO was detected as early as 15 minutes, and the optimal uptake time was 1 to 2 hours. The bars show mean 6 standard error of the mean. Three independent experiments were performed, and three images were used as quantification in each independent experiment. as 30 minutes (Fig 4, A) , persisting up to 2 hours (Fig 4, B) . DT-MPIO targeting was specific to inflamed plaque lesions, without binding to the disease-free aortic root (Fig 4, A) . No binding of IgG-MPIO to inflamed lesions was observed for up to 2 hours.
Secondly, we examined the feasibility of detection of aortic root lesions in ApoE e/e mice by ex vivo in situ MRI after in vivo administration of DT-MPIO (Fig 4, C) . The study also demonstrated the rapid binding of DT-MPIO to atherosclerotic plaques as early as 30 minutes under the in vivo condition. Discrete circular hypointensity signal areas on the luminal side of the aortic root were observed in the DT-MPIO group. We speculate that this resulted from the "blooming effect" caused by the magnetic field distortion of MPIO. This was confirmed by the presence of iron using Perls' stain on aortic root lesions in the matching sections. In contrast, no discrete hypointensity signal was detected in IgG-1-MPIO group, which was confirmed by minimal Perls' stain on the aortic root lesions (Fig 4, C) .
Thirdly, in vivo serial MRI of aortic root was performed from 20 minutes after injection up to 2 hours. In the DT-MPIO group, new hypointensity signal was visualized from 30 to 45 minutes after injection and persisted for the entire 2-hour imaging period (Fig 5, A) . The dark signal appeared to be diffuse, extending between the periluminal and periadventitial regions of the aortic root in the postcontrast images (Fig 5, A) . The hypointensity effect was caused by MPIO binding to plaques, which was confirmed by histology (Fig 5, B) . In the IgG-MPIO group, a negligible degree of homogeneous hypointensity was seen in the postcontrast image (Fig 5, B) . This was supported by minimal binding of the nonspecific IgG-MPIO in the aortic root lesions (Fig 5, B) .
Relationship between markers of plaque inflammation and the magnitude of change in the signal-to-noise ratio. The sample characteristics, mean signal change, and amount of iron binding in the plaques in the two contrast groups are summarized in Fig 6, A and B. Signal change was significantly higher in the mice given DT-MPIO (27.95 6 10.24) than in the IgG-MPIO group (5.58 6 2.87; P < .001). Iron was also higher in the DT-MPIO (7.80 6 1.37) than in the IgG-MPIO group (3.66 6 2.24; P < .001). The DT-MPIO-induced MR signal within plaque lesions was also quantitatively tracked for VCAM-1 (r ¼ 0.69; P ¼ .014), P-selectin (r ¼ 0.65; P ¼ .022), and macrophage burden (r ¼ 0.59; P ¼ .045). In contrast, the IgG-MPIO-induced MR signal did not reflect or track these markers of inflammation within plaque lesions (VCAM-1: r ¼ e0.43; P ¼ .337; P-selectin: r ¼ 0.19; P ¼ .702; and macrophages: r ¼ e0.11; P ¼ .819) (Fig 6, C-E Detection and characterization of vulnerable carotid plaques by in vivo MR angiography using DT-MPIO. A shear stress-modifying cuff was used to induce plaque lesions of both stable and vulnerable phenotypes along the same carotid artery in an ApoE e/e mouse model. In vivo MR angiography (MRA) of carotid arteries was subsequently performed to determine whether DT-MPIO can detect vulnerable plaques. In the DT-MPIO group, new areas of discrete dark signal were detected on the luminal side in the LSS region (upstream or proximal to the cuff) of the right CCA (RCCA) in the postcontrast images of the sagittal, coronal, and axial planes (Fig 7, A) . By contrast, no new discrete dark signal was seen on the luminal side in (1) the HSS region (within the cuff) or (2) OSS region (downstream or distal to the cuff) of the RCCA, and (3) throughout the left CCA (LCCA) in the postcontrast images (Fig 7, A) . In control the IgG-1-MPIO group, no new discrete dark signal was observed in all regions of RCCA and throughout LCCA in postcontrast images. No ill effect or symptom was observed after cuff placement and administration of iron particles until the end of the scanning session. C, Ex vivo magnetic resonance imaging (MRI) of the aortic root after in vivo administration of DT-MPIO for 30 minutes. Dark spots (red arrows) were detected in the aortic root using DT-MPIO (n ¼ 4), but no hypointensity could be detected using control IgG-MPIO (n ¼ 2), as shown in the higher magnification. Perls' stain confirmed the binding of iron particles (blue) to the plaques in aortic root.
Dual-MPIOs selectively bind to lesions with vulnerable plaque phenotype but not to stable lesions. Histologic analysis confirmed that all animals developed lesions in the RCCA in LSS and OSS regions after cuff placement (Fig 7, A) . However, the lesions had a strikingly different morphology. Lesions in the LSS region were characterized by a vulnerable plaque phenotype, (ie, high macrophage content, thin layers of SMCs and collagen in the cap of the lesion). Lesions in the OSS region were characterized by relatively stable phenotype (ie, relatively low macrophage content, thicker layers of SMCs and collagen uniformly distributed in the intima). No atherosclerotic lesion was observed in the HSS region in the RCCA or in the nontreated LCCA.
In the DT-MPIO-treated group, most of the Perls' stain for iron particles was observed in the lesions with a vulnerable phenotype in the LSS region of the RCCA. Minimal Perls' stain was observed in the lesions with a relatively stable phenotype in the OSS region. Absence of Perls' stain was confirmed in the atherosclerosisspared areas in the HSS region in the RCCA and undisturbed control LCCA (Fig 7, A) . The results suggested that DT-MPIO selectively bound not only to lesions but also specifically bound to lesions with vulnerable plaque phenotype. Moreover, the results confirmed that the discrete dark signal detected on the postcontrast MRA in the LSS region on the RCCA was attributable to DT-MPIO targeting at the vulnerable plaque lesions in that region (Fig 7, A) .
The minimal or absent Perls' stain for iron in the histologic sections concurred with the absence of discrete dark signal in the matching postcontrast MRA in the following regions: (1) the lesions of relatively stable phenotype in the OSS region, (2) the atherosclerosisspared areas in the HSS region in the RCCA, and (3) the control LCCA (Fig 7, A) . In the control group, no Perls' stain and therefore no nonspecific IgG-MPIO binding was observed in all regions. The results concurred with To further investigate the differential patterns of MPIO binding in different regions of the carotid artery, expressions of VCAM-1, P-selectin, and macrophage inflammatory protein 3 were examined in each region. The messenger RNA levels of these genes in the LSS region were significantly higher than those in the OSS region, which were in turn, higher than those in the HSS region (Fig 7, B) . The results were also consistent with their expressions at the protein level (Fig 7, C) . These data corroborated that DT-MPIO selectively targeted to the vulnerable inflamed plaques in LSS region, where VCAM-1, P-selectin, and macrophage inflammatory protein 3 were highly expressed, as opposed to plaques with a relatively stable and less inflamed phenotype in the OSS region.
DISCUSSION
Despite Level I evidence, there is no consensus on the best management of patients with asymptomatic carotid artery disease.
14 Even if every asymptomatic patient were to be offered carotid interventions, 95% of all strokes would still occur. 15 Furthermore, 94% of all carotid endarterectomy/carotid artery stenting in asymptomatic patients in the U.S. were ultimately deemed unnecessary, costing U.S. $2 billion annually. 15, 16 The annual stroke risk in patients on the best medical treatment within Asymptomatic Carotid Artery Stenosis Study (ACAS) and Asymptomatic Carotid Surgery Trial (ACST) is diminishing, challenging the propriety of basing contemporary guidelines on historical data. 14 Yet, a small cohort of asymptomatic patients who bear high-risk plaques will undoubtedly benefit from intervention. 17 The next paradigm is to accurately identify and treat these high-risk individuals specifically, rather than continuing with a policy of mass intervention with little benefits for patients in the long-term. Here, we have developed a dual-imaging modality using MRI, fluorescence microscopy, and fluorescentlabeled DT-MPIO to target high-risk inflamed plaques. This molecular imaging strategy benefits from swift binding of MPIO and maintenance of steady state at targets, with rapid clearance of unbound particles from the blood pool, to achieve potent and quantifiable contrast effects in vivo.
USPIOs have been used in the clinical setting for risk stratification because they predominantly accumulate in macrophages within high-risk lesions. 5 However, their relatively long blood half-life, which increases background contrast effects, and the delay between USPIO injection and imaging may restrict widespread clinical use, particularly in the acute setting. The recommended interval of contrast circulation time in most animal models and human studies was 5 to 7 days, 18,19 and 24 to 36 hours, respectively, 20 although the targeted USPIOs that have recently been described have shortened this interval to between 8 and 24 hours in animal models. 21, 22 Moreover, the plaque macrophage population is involved in constant influx and excursion. 23 In the event of acute thromboembolism, such as stroke or myocardial infarction, the delay in imaging may pose a challenge to differentiate whether the signal detected was the result of plaque instability that provoked rupture and symptoms or an after effect of the event.
Compared with nanoscale particles, ligand-conjugated MPIO are potentially better suited for imaging acute inflammatory processes in conditions such as atherosclerosis 12,24,25 and ischemic-reperfusion injury. 26 Our study further elucidated the advantages of DT-MPIO in imaging acute clinical events, which are:
1. The high iron content of MPIOs yields a substantially greater SNR signal-to-noise ratio per particle, with a contrast effect w50 times their physical size. 12 As demonstrated here, such "blooming effect" of MPIOs greatly enhances their sensitivity to achieve in vivo detection of molecular targets. 2. The half-life of our MPIO (1.748 minutes) is significantly shorter than that of nanoparticles. The swift clearance of unbound MPIO from circulation minimizes background blood phase contrast, enhancing the target-to-background ratio and plaque visualization. 3. Similar to previous studies, 12 ,24 the DT-MPIO against VCAM-1 and P-selectin are designed to mimic the rapid binding process of peripheral blood leukocytes to the vessel wall. Here, we have shown the high specificity and synergistically augmented binding of DT-MPIO to VCAM-1 and P-selectin. Owing to the swift antigen-antibody reaction, cellular binding of DT-MPIO occurred #15 minutes and peaked at 1 to 2 hours. Similarly, the DT-MPIO-induced MR signals under the in vivo condition were evident between 30 minutes and 2 hours after injectionda practical imaging interval for acute thromboembolic events. 4 . The large surface area of MPIO enables greater loading capacity of antibodies to these particles, thereby increasing the binding efficiency of targeted MPIO to the adhesion molecules. 5. Quantitative reporting of local plaque inflammatory status is a prime objective in the risk stratification and characterization of atherosclerotic disease. The DT-MPIO-induced MR signal not only reflected the degree of inflammation but also tracked closely with VCAM-1 and P-selectin expression under both in vitro and in vivo conditions. This concurred with our earlier work that characterized these inflammatory markers on activated ECs 27 and human carotid plaques 11 by MRI using antibody-conjugated SPIO. The present results affirm that the MRI combined with the DT-MPIO approach could potentially offer a novel imaging tool for quantitative assessment of inflammation across a range of atherosclerotic lesions complexities in the future. The potent contrast sensitivity, rapid binding, and clearance kinetics of DT-MPIO facilitate an evident "targetto-background" and quantifiable contrast effect within a practical imaging time frame. This distinguishes DT-MPIO as a valuable molecular imaging platform in the context of imaging acute clinical events. If reproduced in humans, these characteristics would be ideal for clinical application.
To date, the degree of luminal stenosis alone assessed by conventional angiographic techniques has not been effective in identifying the high-risk asymptomatic subgroup patients.
14 Studies have used the periarterial collar to induce atherosclerosis in the mouse model for molecular MRI. In this study we further demonstrate that an in vivo molecular MRI strategy can be used to differentiate the heterogeneity (ie, stable vs unstable lesions) within the asymptomatic plaque population and to identify high-risk vulnerable plaques in the murine carotid artery within a practical imaging time frame. Another interesting finding is that outward remodeling of the carotid artery (Fig 7, A) left the lumen relatively patent, which would mean the high-risk plaques would remain undetected by conventional MRA. However, the high-risk plaques were detected by DT-MPIO-enhanced MRA. The molecular MRI strategy may potentially overcome the limitation of current angiographic techniques by interrogating the inflammatory status within the HE, Hematoxylin and eosin. B, Highest messenger RNA (mRNA) levels of vascular cell adhesion molecule 1 (VCAM-1), P-selectin, and macrophage inflammatory protein 3 (MIP-3) were detected in the region of LSS, followed by OSS and then HSS of the RCCA, indicating that the lesions at the LSS region were more inflamed than those in OSS or HSS regions (n ¼ 3). C, Protein levels of VCAM-1, P-selectin, and MIP-3 were consistent with mRNA levels (n ¼ 3). Data are shown as the mean 6 standard error of the mean. *P < .05.
plaques. The lesions were induced in the carotid artery instead of other vascular beds, moving a step closer to translating this in vivo imaging strategy to patients with carotid atherosclerotic disease. No obvious cytotoxicity or ill effects of the MPIO on the animals were observed. Iron particles, being biodegradable, have a satisfactory biocompatibility profile. 28, 29 A number of agents with iron particles, such as ferumoxytol, have been clinically approved as an MRI contrast medium or as an iron replacement product for treatment of iron-deficiency anemia. 29 The biosafety of iron particles via the intravenous route is also witnessed in imaging human carotid atherosclerosis 30 and treatment for iron-deficiency anemia in patients with chronic kidney disease, 31 indicating that these products have a reasonable safety profile corresponding to standard toxicologic and pharmacologic tests. 32 The dose of MPIO administered in our study was 5 mg iron/kg body weight, which was slightly higher than that used clinically for nontargeted iron contrast agents in human oncologic imaging (2.6 mg/kg) 33 but was significantly lower than some USPIO doses used experimentally for imaging larger animal models such as rabbits (11-56 mg/kg). 34, 35 A relatively high dose was used in this study to see whether the signal attenuation was feasible for detection of atherosclerotic lesions. Further optimization of the dose of MPIO is warranted in future studies. Although evident contrast effect was achieved in this study, further optimization of the MR sequence can increase the contrast signal for in vivo detection of molecular targets. The DT-MPIO in this study was synthesized by using two separate antibodies to target against VCAM-1 and P-selectin. The two separate antibodies can be replaced by a direct conjugation of bispecific antibodies, which simultaneously target both VCAM-1 and P-selectin, to the MPIO to further increase the specificity of DT-MPIO. Although this molecular imaging tool has been validated in various stages, we hope to repeat with a larger sample size in large animal model.
CONCLUSIONS
With the ongoing CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Study Primary Prevention of Stroke) and ACTRIS (Endarterectomy Combined With Optimal Medical Therapy [OMT] vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-Than-Average Risk of Ipsilateral Stroke) studies evaluating imaging features in high-risk asymptomatic cohorts, we hope this molecular MRI tool can potentially allow characterization of plaque vulnerability and quantitative imaging of inflammatory activity in atherosclerosis in the future. This facilitates accurate risk stratification of individual patients and identification of the high-risk patient subgroup with unstable inflamed plaque disease, affording the opportunity for early preventive intervention and paving the way for personalized management of carotid artery disease. This work will form the basis for a translational study with direct clinical relevance to patients with cerebrovascular diseases. In vitro DT-MPIO binding to tumor necrosis factor-a stimulated cells. Mouse endothelial cells (C166), mouse macrophage (RAW 264), and mouse aorta smooth muscle cells (MOVAS) were cultured in a 15-cm culture dish with coverslips. They were incubated with different doses (0, 0.1, 1, 10, and 100 ng/mL) of murine recombinant tumor necrosis factor-a (TNF-a; Sigma-Aldrich, St. Louis, Mo) for 24 hours at 37 C to induce inflammation and expression of VCAM-1 and P-selectin. Before the addition of MPIO, coverslips in each culture dish were taken out for the determination of VCAM-1 and P-selectin expression by immunocytochemistry. The remaining stimulated cells in the 15-cm culture dish were incubated with VCAM-1-MPIO, P-selectin-MPIO, DT-MPIO, or IgG-MPIO (2 mg/3 Â 10 6 cells) for 1 hour at 37 C. Cells were repeatedly rinsed with PBS to remove unbound MPIO. Cell-bound MPIO was directly observed under fluorescence microscope, and the area per cell in a microscopic field was quantified using ImageJ (National Institutes of Health, Bethesda, Md) public domain software. Briefly, the area of MPIO binding in a microscopic field was quantified by ImageJ, the number of cells in that field was counted, and the area of cell bound-MPIO per cell in each field was obtained. Three microscopic fields were chosen in each field, and three independent experiments were performed; therefore, the histologic quantification is the mean of nine data.
APPENDIX (online only).

Supplementary methods
For the time-point experiment, the cells were incubated with 10 ng/mL TNF-a for 24 hours at 37 C, followed by DT-MPIO incubation for 0, 15, 30, 60, 120, and 240 minutes. For the blocking experiment, the VCAM-1 and Pselectin target sites expressed on TNF-a-treated cells (10 ng/mL) were initially blocked by single or both primary antibodies (anti-VCAM-1 and anti-P-selectin) before incubation with DT-MPIO. The area of cell-bound MPIO per cell was assessed as described above. Three independent experiments were performed. , and a monochrome charge coupled device camera (Olympus) driven using CellSens (Olympus) were used. VCAM-1 and P-selectin fluorescence intensity per cell were quantified using ImageJ. Cell growth and survival assay. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was conducted to assess cell survival and growth after addition of DT-MPIO. Endothelial cell lines were first stimulated by TNF-a (10 ng/mL at 37 C for 24 hours) before incubation with different concentrations of DT-MPIO (0 to 2 mg/mL) for 24 hours. Reference control was also done with the cell line without stimulation of TNF-a to eliminate the toxic effect of TNF-a before MPIO was added. The MTT assay was conducted according to the manufacturer's manual (Cayman Chemical Co, Ann Arbor, Mich).
Biodistribution. For biodistribution, DT-MPIO was injected in the via tail vein (n ¼ 3 apolipoprotein E deficient [ApoE e/e ] mice per group) and allowed to circulate for 0, 0.5, 6, 24, 48, and 72 hours. Mice were terminally anesthetized. Lung, liver, spleen, and kidney were collected and weighed before quantification of magnetic particles (Pepric, Leuven, Belgium). Calibration was done by varying known MPIO amount (0-1 mg) .
Immunohistochemistry of aortic root. At the end of MPIO circulation or imaging, the mouse was euthanized and the heart was excised. The upper part of the heart was cut at the base of the aortic valves, embedded in Tis Air-dried cryostat sections of the aortic root were fixed with precooled acetone for 10 minutes at room temperature and rinsed with PBS three times. Nonspecific staining was blocked by incubation with 3% BSA in PBS for 30 minutes and then washed in PBS. Slides were incubated with primary antibody in a 1:50 dilution at 4 C overnight, followed 1:200 dilution of secondary antibodies for 1 hour at room temperature. Whole-slide images were produced using Olympus IX-83 inverted microscope, as previously described. In the vivo experiment, the histologic staining in all images was quantified using ImageJ. The area of the aortic root was outlined, and the fluorescent-stained area was quantified within the aortic root. The stained area of VCAM-1, P-selectin, monocyte/macrophage marker antibody, and MPIO were quantified as a percentage area of the total aortic root area. For each staining in each animal, one tissue section at three different levels was chosen, and the mean of each staining in these three sections was obtained. Twelve mice were used in DT-MPIO group, and seven mice were used in IgG-MPIO group.
Animals and in vivo administration of DT-MPIO. All animal experiments were performed in accordance with UK Scientific Procedures Act (1986) and local ethical approval. Homozygous ApoE e/e mice (70 weeks old) were fed a standard mouse chow diet until the day of the experiment. DT-MPIO or control IgG-MPIO were injected with 5 mg iron/kg body weight in 150 mL PBS via the tail vein, which was allowed to circulate for 0, 0.5, 1, 1.5, and 2 hours. Mice were then anesthetized and underwent magnetic resonance imaging (MRI) scanning or histologic analysis, or both.
Ex vivo in situ MRI after systemic administration of dual-targeted MPIO. DT-MPIO (n ¼ 4 mice) or control IgG-MPIO (n ¼ 2 mice) were injected with 5 mg iron/kg body weight in 150 mL PBS via the tail vein, which allowed to circulate for 30 minutes. ApoE e/e mice were euthanized and perfusion fixed with 4% paraformaldehyde. Ex vivo in situ MRI of the aortic root was performed with a Direct Drive 9.4T Varian (Palo Alto, Calif) horizontal bore scanner with 100 G/cm gradients and bird cage radiofrequency coil (RAPID Biomedical GmbH, Rimpar, Germany) with a 33-mm internal diameter running VnmrJ 2.3A software (Agilent, Santa Clara, Calif Quantitative MRI analysis of the aortic root. Using the aortic valves as a reference marker, the inner and outer contours of the aortic root were delineated manually and independently by two observers and defined as the region of interest (ROI). The signal within the ROI (plaque signal) and that of a similarly sized ROI in the background noise were measured using ImageJ software, The signal-to-noise ratio (SNR) of the ROI was calculated as: SNR of ROI ¼ (signal within ROI)/(signal in background noise). The mean of SNRs of all three consecutive slices per subject was calculated.
Implantation of shear stress-modifying cuff in carotid arteries. The shear stress-modifying cuff (provided by authors C.M. and K.K.B.) and implantation procedure were described in previous studies. 13 The cone-shaped inner lumen is imperative for creating defined regions of low shear stress (LSS) upstream, high shear stress (HSS) within the cuff, and oscillatory shear stress (OSS) downstream within the common carotid artery (CCA). 13 At age 18 weeks, the ApoE e/e mice were fed an atherogenic diet 2 weeks before cuff implantation until the day of scanning. At week 20, surgical implantation of the shear stress-modifying cuff was performed on one of the CCAs while the other CCA was left untreated as a control. Histology of carotid arteries. At the end of the scanning session, the ApoE e/e mice were euthanized, the arterial tree was perfusion fixed, and the cuff was removed. To determine which phenotypes of carotid plaques were targeted by DT MPIO, serial 4-mm-thick paraffin sections of the entire carotid artery across all three shear-stress regions underwent staining for iron (Perls') and connective tissue (picrosirius red), and immunostaining for macrophages (Mac-3), and smooth muscle cells (a-SMA). Perl's staining was performed. The tissue sections were stained in solution (one part 0.05 mol/L potassium ferrocyanide and 1 part 0.25 mol/L hydrochloric acid) for 15 minutes. The tissue sections were rinsed with water and counterstained with filtered neutral red stain for 1 minute. The sections were rinsed, dehydrated with ethanol, and cleared with xylene. Microscopy was performed.
Messenger RNA quantification in carotid artery by reverse transcriptase polymerase chain reaction. The treated CCA of mice was divided into three regions: OSS, HSS, and LSS. Each region of eight mice was collected into a tube for exaction of RNA, DNA, and protein. Three independent experiments were performed.
Total RNA from each region of the carotid arteries was separately homogenized and extracted with the RNA/ DNA/Protein kit (Invitrogen) according to the manufacturer's protocol. The concentration of total RNA was determined by NanoDrop ND-1000 Spectrophotometer Protein expression in the carotid artery by Western blotting. Protein lysates of each region of the carotid arteries were isolated from the kit described above and were quantified by the bicinchoninic acid protein assay kit (Pierce Biotechnology). Protein samples (30 mg) were separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred into nitrocellulose membranes (Bio-Rad Laboratories, Hercules, Calif). The membrane was blocked with 5% nonfat milk in Tris-buffered saline-Tween buffer and then probed overnight at 4 C with anti-VCAM-1 (1:1000), anti-Pselectin (1:1000), antimacrophage inflammatory protein 3 (1:1000, Abcam), and anti-b-actin (1:2000; Cell Signaling Technology, Danvers, Mass). This was followed by appropriate secondary antibodies conjugated to horseradish peroxidase (1:5000) for 1 hour. After washing, the membrane was developed with an enhanced chemiluminescence kit (Amersham Pharmacia Biotechnology, Piscataway, NJ) and exposed to x-ray films (Amersham Pharmacia Biotechnology). Intensity of bands was quantified using ImageJ software. Equal loading was corrected by b-actin immunoreactivity.
Statistical analysis. The percentage change of the mean SNR signal, VCAM-1, P-selectin, macrophages, and iron were summarized as mean (standard deviation) and compared between DT-MPIO and control IgG-MPIO mice using t-tests. The correlations between the signal change and each of the other variables were estimated within each contrast group using the Spearman rank correlation coefficient (r). Linear models were used to assess whether the strength of the association between each of the biomarkers and the signal change differed by contrast groups. Each model included the biomarker (where signal change was the outcome of interest) and contrast groups as main effects and an interaction between groups and biomarkers. The interaction term was used to determine whether the strength of the relationship differed between the contrast groups. The nature of the relationship between VCAM-1 and P-selectin and their effect on signal change under contrast groups was also explored by including an interaction between VCAM-1 and P-selectin. Intraobserver and interobserver variability in measurement of percentage change of SNR in aortic vessel wall were analyzed using Bland-Altman plot. All tests were two sided, and P < .05 was considered statistically significant. Analysis was conducted using Stata 13MP software (StataCorp LP, College Station, Tex).
